MedTrace Logo

ALPN-202 With PD-1 Inhibition in Advanced Malignancies

NCT04920383 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2024-03-01

No results posted yet for this study

Summary

This is a cohort-based, open-label dose escalation and expansion study in adults with advanced solid tumors or lymphoma.

Conditions

Interventions

DRUG

ALPN-202

Various doses

DRUG

pembrolizumab KEYTRUDA®

Varies

Sponsors & Collaborators

Principal Investigators

  • Allison Naumovski, Ph.D. · Alpine Immune Sciences

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-22
Primary Completion
2022-11-08
Completion
2023-02-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04920383 on ClinicalTrials.gov